- Home
- BMY
as 11-18-2025 3:36pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 95.0B | IPO Year: | N/A |
| Target Price: | $55.64 | AVG Volume (30 days): | 16.4M |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $42.52 - $63.33 | Next Earning Date: | 10-30-2025 |
| Revenue: | $48,034,000,000 | Revenue Growth: | 1.26% |
| Revenue Growth (this year): | -0.3% | Revenue Growth (next year): | -8.08% |
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
![[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)](/cdn/transform/width=500,quality=90,format=webp/https://cdn.finquota.com/news/127637f7-8942-4dc2-9419-357c408257d1.png)
GlobeNewswire
a day ago
[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
StockStory
a day ago
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3
Business Wire
a day ago
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
Zacks
2 days ago
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
Barchart
2 days ago
Stocks Set for Muted Open as Investors Await Nvidia Earnings and U.S. Jobs Data
MT Newswires
2 days ago
Mesoblast Appoints James O'Brien CFO
StockStory
2 days ago
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
Insider Monkey
3 days ago
Scotiabank Initiates Coverage on Bristol Myers (BMY) with Sector Perform Rating and $45 Target
Compare BMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.